Toxicological Sciences, Vol 49, 324-331, Copyright © 1999 by Society of Toxicology
N Sagara-Ishijima and K Furuhama
We compared lethal toxicity and potential for splenomegaly and disseminated
intravascular coagulation (DIC) of the lipid A derivative DT-5461 with
those of compound 506 (C506) and bacterial lipopolysaccharide (LPS). These
agents were given intravenously, by either bolus intravenous injection (2
ml/min) or drip infusion (3 ml/4 h), into the tail vein of rats under
various regimens. In naive rats, the lethal dose after bolus intravenous
injection was clearly higher than that after drip infusion for C506 and
LPS, but not for DT-5461. In partially hepatectomized or
D-galactosamine-treated rats, a marked enhancement of the lethality was
observed for all agents relative to that in naive rats. Splenomegaly was
commonly seen in all surviving rats after treatment, and histopathological
examination revealed lymphoid hyperplasia in the B-cell area of the white
pulp zone and lympho-reticular cell proliferation of the red pulp zone.
When administered intravenously by drip infusion to rats pretreated with
0.4 M lactic acid, both C506 and LPS provoked DIC. This was manifested by a
decrease in platelet counts, prolongation of activated partial
thromboplastin time (APTT), and an increase in fibrin-fibrinogen
degradation products (FDP), with hepatocellular necrosis and glomercular
fibrin thrombus formation. In contrast, DT-5461 showed no such toxic events
with the same protocol. In14-day intravenous toxicity studies of DT-5461,
rats were more susceptible to hepatocellular necrosis and splenomegaly than
squirrel monkeys. These results demonstrate that DT-5461 is a promising
compound, with antitumor activity dissociated from its toxic potential.
ARTICLES
Toxic characteristics of the synthetic lipid A derivative DT-5461 in rats and monkeys
Tokyo Research and Development Center, Daiichi Pharmaceutical Co., Ltd., Japan.
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
R. Silverstein Review: D-Galactosamine lethality model: scope and limitations Innate Immunity, June 1, 2004; 10(3): 147 - 162. [Abstract] [PDF] |
||||
